65,437 trials
Bile Acid Malabsorption · Cholelithiasis
Primary: Change in Stimulated Fibroblast Growth Factor 19 (FGF19) From Baseline Before Versus Post Cholecystectomy — 81; 186 pg per mL — p=0.03
Healthy · Chronic Rhinosinusitis With Nasal Polyps · Atopic Dermatitis
Primary: Number of Participants With All-causality Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Part 1 — 6; 4; 5; 3 Participants
Peanut Allergy
Primary: Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 444 mg (Cumulative) Peanut Protein at Week 24 — 8.3 Percentage of Participants
Healthy Subjects · Changes Based on Duration of Tape Application · Direction of Kinesio Tape Application
Primary: Vertical Jump Height Immediately Post Tape Administration — 41.6; 41.1 centimeters
Child Abuse · Posttraumatic Stress
Primary: Change in Scores on the UCLA Posttraumatic Stress Disorder Reaction Index — 44.63; 39.5; 22.64; 35.85 units on a scale
Pain, Acute · Anesthesia, Local · Trauma Injury
Primary: Average Pain Queried on First Postoperative Day — 3; 0.0 score on a scale — p=0.033
Hypogonadism · Peripheral Vascular Disease · Type 2 Diabetes
Primary: Change in Arterial Stiffness — 15.02; 15.08; 14.08; 16.12 index β
Whooping Cough
Primary: Incidence Rate (Per 1000 Person-years) of Pre-specified Maternal Adverse Events for Exposed Cohort women-on or After 1st Day of 27th Week of Pregnancy and Unexposed…
Renal Cell Carcinoma · Melanoma
Primary: Percentage of Participants With Dose-limiting Toxicities (DLTs) (Part 1A) — 36.4; 25; 20; 0.0 Percentage of Participants
Prostate Cancer
Primary: MP-erMRI Classification Sensitivity — 0.875 proportion of true positives
Postoperative Wound Infection Deep Incisional Surgical Site · Prosthesis and Implants · Surgical Site Infection
Primary: Number of Participants With Bacterial Growth Before and After Photodynamic Treatment and After Skin Antisepsis — 10; 10; 3; NA Participants
Castration-Resistant Prostate Carcinoma · Prostate Adenocarcinoma
Primary: Percent of Patients With a Prostate-specific Antigen (PSA) Decline of at Least 50% Below Baseline PSA50 Response Rate — 14 Participants
Visual Acuity
Primary: CLUE Comfort Score — 65.95; 65.13; 67.39; 70.80 Units on a scale
Cardiac Disease · Heart Failure · Coronary Artery Disease
Primary: Number of Participants With Major Infection Post Procedure — 2; 0; 0 Participants
Septoplasty
Primary: Percentage of Participants With Clinical Success of the ENTACT Septal Staple System by Examining the Participant's Nasal Cavity at the 21 Day Follow-up Visit — 94.7…